EUVIMEDEUVIMED entdecken
Crossref

Clinical evaluation of [18F]pitavastatin for quantitative analysis of hepatobiliary transporter activity

Takayoshi Nakaoka, Ken-Ichi Kaneko, Satsuki Irie, Aya Mawatari, Ami Igesaka, Yuta Uetake, Hidenori Ochiai, Takashi Niwa, Emi Yamano, Yasuhiro Wada, Masaaki Tanaka, Kohei Kotani und 9 weitere

Drug Metabolism and Pharmacokinetics · 2022-06 · 44 · 100449

DOI: 10.1016/j.dmpk.2022.100449 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Metabolism and Pharmacokinetics, 2022-06. Verfasst von Takayoshi Nakaoka und 20 weiteren Autor:innen. Beteiligte Einrichtung: RIKEN Center for Life Science Technologies CLST, 6-7-3 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan; RIKEN Center for Biosystems Dyn…. Hauptthemen laut MEDLINE: Quinolines, Rifampin. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

It is widely accepted that uptake and efflux transporters on clearance organs play crucial roles in drug disposition. Although in vitro transporter assay system can identify the intrinsic properties of the target transporters, it is not so easy to precisely predict in vivo pharmacokinetic parameters from in vitro data. Positron emission tomography (PET) imaging is a useful tool to directly assess the activity of drug transporters in humans. We recently developed a practical synthetic method for fluorine-18-labeled pitavastatin ([18F]PTV) as a PET probe for quantitative evaluation of hepatobiliary transport. In the present study, we conducted clinical PET imaging with [18F]PTV and compared the pharmacokinetic properties of the probe for healthy subjects with or without rifampicin pretreatment. Rifampicin pretreatment significantly suppressed the hepatic maximum concentration and biliary excretion of the probe to 52% and 34% of the control values, respectively. Rifampicin treatment markedly decreased hepatic uptake clearance (21% of the control), and moderately canalicular efflux clearance with regard to hepatic concentration (52% of the control). These results demonstrate that [18F]PTV is a useful probe for clinical investigation of the activities of hepatobiliary uptake/efflux transporters in humans.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

QuinolinesRifampinBiological TransportHumansLiverMembrane Transport Proteins

Stichwörter der Autor:innen

(18)F]pitavastatinCanalicular efflux clearanceDrug-drug interactionHepatic uptake clearanceHepatobiliary transporter activityPositron emission tomographyRifampicin

Substanzen

Membrane Transport ProteinsQuinolinespitavastatinRifampin

Autor:innen und Institutionen

  • RIKEN Center for Life Science Technologies CLST, 6-7-3 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan; RIKEN Center for Biosystems Dynamics Research BDR, 6-7-3 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo…
  • RIKEN Center for Life Science Technologies CLST, 6-7-3 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan.
  • RIKEN Center for Biosystems Dynamics Research BDR, 6-7-3 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan.
  • Department of Physiology, Graduate School of Medicine, Osaka City University, Abeno-ku, Osaka, 545-8585, Japan.
  • Department of Hepatology, Graduate School of Medicine, Osaka City University, Abeno-ku, Osaka, 545-8585, Japan.
  • Department of Radiology, Osaka City University Hospital, Abeno-ku, Osaka, 545-8586, Japan.

Zitieren

APA

Nakaoka, T., Kaneko, K. I., Irie, S., Mawatari, A., Igesaka, A., Uetake, Y., Ochiai, H., Niwa, T., Yamano, E., Wada, Y., Tanaka, M., Kotani, K., Kawahata, H., Kawabe, J., Miki, Y., Doi, H., Hosoya, T., Kazuya, M., Kusuhara, H., …, & Watanabe, Y. (2022). Clinical evaluation of [18F]pitavastatin for quantitative analysis of hepatobiliary transporter activity. Drug Metabolism and Pharmacokinetics, 44, 100449. https://doi.org/10.1016/j.dmpk.2022.100449

Vancouver

Nakaoka T, Kaneko KI, Irie S, Mawatari A, Igesaka A, Uetake Y, et al. Clinical evaluation of [18F]pitavastatin for quantitative analysis of hepatobiliary transporter activity. Drug Metabolism and Pharmacokinetics. 2022;44:100449. doi:10.1016/j.dmpk.2022.100449

BibTeX
@article{Nakaoka2022,
  author = {Nakaoka, Takayoshi and Kaneko, Ken-Ichi and Irie, Satsuki and Mawatari, Aya and Igesaka, Ami and Uetake, Yuta and Ochiai, Hidenori and Niwa, Takashi and Yamano, Emi and Wada, Yasuhiro and Tanaka, Masaaki and Kotani, Kohei and Kawahata, Hideki and Kawabe, Joji and Miki, Yukio and Doi, Hisashi and Hosoya, Takamitsu and Kazuya, Maeda and Kusuhara, Hiroyuki and Sugiyama, Yuichi and Watanabe, Yasuyoshi},
  title = {Clinical evaluation of [18F]pitavastatin for quantitative analysis of hepatobiliary transporter activity},
  journal = {Drug Metabolism and Pharmacokinetics},
  year = {2022},
  volume = {44},
  pages = {100449},
  doi = {10.1016/j.dmpk.2022.100449}
}
Kostenlos starten →